Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion

A Prospective Randomized Trial Comparing Treatment of Recurrent HCC With Repeat Hepatectomy,and Transcatheter Arterial Chemoembolization (TACE) With AFP Conversion

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02728219

Acronym

HCCTACEAFP

Enrollment

150

Registered

2016-04-05

Start date

2012-05-31

Completion date

2015-05-31

Last updated

2016-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Hepatocellular Carcinoma

Keywords

Recurrent Hepatocellular Carcinoma, transcatheter arterial chemoembolization, AFP conversion

Brief summary

The purpose of this study is to compare the treatment of recurrent hepatocellular carcinoma with repeat hepatectomy,and transcatheter arterial chemoembolization (TACE) with AFP conversion.

Detailed description

Though many HCC patients have been benefited from hepatectomy treatment, still the high recurrence rate after the hepatectomy led to limited effectiveness. This is the first study in same case system on comparison of effectiveness among repeat hepatectomy, and TACE with AFP conversion.

Interventions

PROCEDURETACE

In this study we prospectively select some early diagnosed recurrent HCC patients after radical resection with AFP conversion, then they will be treated with transcatheter arterial chemoembolization (TACE)

PROCEDUREHepatectomy

Repeat Hepatectomy after postoperation recurrence

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. via clinical diagnosis and confirm it is early recurrent liver cancer with AFP conversion, and not accept any anticancer treatment. 2. age:18-70years 3. better liver function (Child-Pugh，class A or B)

Exclusion criteria

1. reject to attend； 2. impossible to come to our hospital for physical examination regularly. 3. cancer epitome、seed focus、lymph node or distant metastasis 4. Blood clotting function hindrance; 5. serious heart、lung、kidney disease

Design outcomes

Primary

Measure	Time frame
overall survival	3 years

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026